“You are only entitled to the action, never to its fruits.” — Bhagavad Gita

💡🔥Out today, the Oncogene-addicted metastatic NSCLC ESMO Guideline. A significant effort to improve the management of patients w/ #lungcancer harbouring 🔟 different gene alterations! This is an amazing manuscript & I am glad to be a part of it #LCSM sciencedirect.com/science/articl…

📣Attention all clinicians! Don't miss out on our webinar, "Be Alert! Oncology Has Emergencies Too," featuring Dr. Najihah Abu Bakar from Hospital Raja Permaisuri Bainun and Dr. Tan Chih Kiang from Tung Shin Hospital. Register NOW - docquity.app.link/ytHdn161Axb #docquity #oncology

Great privilege to have Daniel Heng to join us in #recap2023 in Malaysia 🇲🇾. SIU-Urology European Association of Urology (EAU) Wei S Yeoh Faculty of Medicine, Universiti Malaya Universiti Malaya UM_urology UM Specialist Centre

Great start to RECAP 2023! Renal cancer preceptorship with urologists and oncologist onboard. Great speakers line up Daniel Heng & Ravindran Kanesvaran #recap2023

We are looking for patients with Non-Small Cell Lung Cancer condition. Visit the link below if you are interested to partake in our clinical trial! clinicalresearch.my/condition/non-… #findaclinicaltrial #clinicalresearchmy #nsclc

Interesting thread on AI in the field of oncology.

The ADAURA adjuvant study in NSCLC now met the endpoint of Overall Survival ! Major win for patients ! astrazeneca.com/media-centre/p… OncoAlert ASCO ESMO - Eur. Oncology Oncology Brothers

Please join this terrific meeting in #Portsmouth (either in-person or virtual) planned by Giuseppe Banna & Ravindran Kanesvaran! Should be an excellent session that spans #prostatecancer, #bladdercancer and #kidneycancer - eager to present alongside Neeraj Agarwal, MD, FASCO, Alison Tree 💙,

.Eric Lim presents MARS2. Undoubted reduced survival with surgery (EPD) n=355. 28% increased risk of death. No difference due to chemo impact. QOL worse for surgery. Time to dismiss the concept of resectability #WCLC23 IASLC #mesothelioma

🚨#WCLC23 Ph3 #FLAURA2 Primary endpoint: 𝐏𝐅𝐒 𝐛𝐲 𝐢𝐧𝐯 ▪️PFS:Osi+chemo 𝘷𝘴. Osi: 25.5 𝘷𝘴. 16.7 HR 0.62; p<0.0001; 51% maturity ▪️OS was immature (27%) HR 0.90; p=0.52 ▪️G ≥3 AEs: 64%/27% A positive study to integrate w/ many Ph3 trials ready to be out in this field

Excellent faculty & series of GU Onco talks virtually International Urology Cancer Summit Thank you for a well organised summit & taking on pertinent questions. Ravindran Kanesvaran Giuseppe Banna OncoAlert Gil Morgan, MD ONCOassist® | The go-to oncology app #IUCS23

Tuning in to #RCR23 virtually this year round. Hoping to be in person for next year. The Royal College of Radiologists

Interesting session on AI & auto-contouring at #RCR23 Focus on OAR currently however may start to incorporate treatment volumes. Critical space to watch? The Royal College of Radiologists

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

AstraZeneca and the Lung Cancer Network Malaysia collaborate to offer free AI-powered lung screening and expert consultations. codeblue.galencentre.org/2023/11/16/all…

New chapter at Leeds Cancer Centre

Awesome radiotherapy symposia at #BTOG25 including stellar talks from Houda Bahig, MD PhD Matthias Guckenberger & Matthew Evison My overall take-home: non-RT factors have never been more important for unravelling the toxicity that restricts how we expand our application of RT in lung cancer!

Productive day 1 of BTOG 2025. BTOG Leeds Teaching Hospitals

Amazing session on SCLC at BTOG Stephen V Liu, MD Jarushka Naidoo Anna Minchom Gerard Walls BTOG